Page 1

We are proud to introduce our

2014 BMT Tandem Meeting Speakers: Wednesday, February 26, 2014 PODIUM PRESENTATIONS Alan Hanash

The GI Crypt as a Target of GVHD 10:30 AM-12:00 PM

Sergio Giralt

Strategies to Accurately Risk-Stratify Multiple Myeloma Patients 12:30 PM-1:30 PM

Miguel-Angel Perales

BMT CTN 1301 PROGRESS II (CNI-Free GVHD Prophylaxis) 2:45 PM-4:30 PM

POSTER PRESENTATIONS - 6:45 PM-7:45 PM Kamal Abbi, Sean Devlin, Sergio Giralt and Heather Landau

Craig Moskowitz

Saliangi Wu

Second Autologous Stem Cell Transplant: An effective therapy for relapsed multiple myeloma with chemo-sensitive disease

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

Juliet Barker

Farid Boulad

Christopher J. Forlenza

Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery

Parastoo Dahi

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Non-Malignant Hematologic Disorders (NMHD), Using a Chemotherapy-Only Cytoreductive Regimen and T-Cell Depleted Grafts from Alternative Donors

Comparative Analysis of T-Cell Depleted Matched Vs Mismatched Unrelated DONOR Transplants in Patients with Hematologic Malignancies

Busulfan, Melphalan, and Thiotepa Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) of Pediatric Patients with Acute Leukemia and Central Nervous System (CNS) Disease

Aisha Nasreen Hasan

Generation and Characterization of a Third Party GMP Grade Bank of CMV Specific T-Cells for Adoptive Immunotherapy of CMV Infections in Recipients of HSCT from Cord Blood or Seronegative Donors

Luciano J. Costa (Heather Landau, Guenther Koehne, David Chung, Nikoletta Lendvai and Sergio Giralt)

Phase 1 Trial of Carfilzomib + Melphalan (CarMel) Conditioning and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Relapsed Multiple Myeloma (MM)

Prospective Evaluation of Alternative Donor Availability in 708 Patients: Improved Allograft Access with Enlarging Cord Blood (CB) Inventory for All Patients Including Racial and Ethnic Minorities

Thursday, February 27, 2014 PODIUM PRESENTATIONS Marcel R. M. van den Brink

The Role of Neovascularization in Graft-Versus-Host Disease and Graft-Versus-Tumor Activity 8:30 AM-10:00 AM

Miguel-Angel Perales and Alberto Mussetti

How to Select the Best Cord Blood Unit 1:15 PM-2:45 PM

CIBMTR Working Committee Proposal: Evaluation of three alternative donor strategies for patients with hematologic malignancies: Comparison between unrelated double umbilical cord blood (dUCB) and HLA-haploidentical related donor using either post transplant cyclophosphamide or ex vivo T cell depletion 2:45 PM-4:45 PM

Miguel-Angel Perales

Valkal Bhatt

Andromachi Scaradavou

CIBMTR Working Committee: Graft Sources and Manipulation 2:45 PM-4:45 PM

Long Term Complications of Hematopoietic Stem Cell Transplantation 4:15 PM-5:15 PM

Genovefa Papanicolaou

Prospective PCR Monitoring Reveals Adenovirus (ADV) Viremia Is Associated with a Significant Risk of ADV Disease in T-Cell Depleted and Cord Blood Allograft Recipients 4:15 PM-5:15 PM

Stephen Harnicar

Higher Mycophenolic Acid (MPA) Through Levels Result in Lower Day 100 Severe Acute Graft-Versus-Host Disease (aGVHD) without Increased Toxicity in Double-Unit Cord Blood Transplantation (CBT) Recipients 4:15 PM-5:15 PM

Caroline Lindemans

IL-22 Administration Protects Intestinal Stem Cells from GVHD 4:15 PM-5:15 PM

Leyla Shune

Robust Vaccine Responses in Double-Unit Cord Blood Transplantation (CBT) Recipients Despite Lack of Transfer of Memory T and B Cells 4:15 PM-5:15 PM

Vinod K. Prasad (Genovefa Papanicolaou)

Brincidofovir (CMX001) Is Well-Tolerated in Highly Immunocompromised Pediatric Patients 4:45 PM-6:15 PM

Friday, February 28, 2014 PODIUM PRESENTATIONS Karen Collum

David Chung

Guenther Koehne

Richard Mitchell

Integrating Quality Reporting into the Electronic Medical Record 9:30 AM-10:15 AM T-Cell Depleted Allogeneic HSCT for Patients with Relapsed, High-Risk Multiple Myeloma Permits Long-Lasting Remissions in the Absence of Graft-Versus-Host Disease and Provides a Platform for Adoptive Immunotherapeutic Approaches 10:30 AM-12:00 PM

Immune Reconstitution after Autologous Stem Cell Transplantation for Multiple Myeloma 10:30 AM-12:00 PM Intrathecal Chemotherapy Post Hematopoietic Cell Transplantation for Prevention of Central Nervous System Relapse in Pediatric Acute Leukemia 10:30 AM-12:00 PM

Janet Eagan

BMT Isolation, Infection Control & Diet Rituals 2:45 PM-4:15 PM

Yusuke Shono

ATG16L1 Prevents Lethal T-Cell Alloreactivity Mediated By Dendritic Cells 4:45 PM-6:30 PM

Robert Jenq

Identification of Intestinal Commensal Bacteria Protective Against Gvhd in Mice and Humans 4:45 PM-6:30 PM

Richard O’Reilly E. Donnall Thomas Lecture 7:35 PM-8:15 PM

Saturday, March 1, 2014 PODIUM PRESENTATIONS Miguel-Angel Perales

The ASBMT Clinical Case Forum: More lessons from Dr. Who on Regenerating the BMT Workforce: “Is it Always This Dangerous?” 7:00 AM-8:30 AM

Miguel-Angel Perales Immune Reconstitution 8:45 AM-9:30 AM

Sergio A. Giralt

Juliet Barker

Cord Blood Transplantation 12:15 PM-1:30 PM

Doris Ponce

High Disease-Free Survival and Enhanced Protection Against Relapse after Double-Unit Cord Blood Transplantation (DCB-T) When Compared to Unrelated Donor Transplantation (URD-T) in Patients with Acute Leukemia, MDS and CML 4:45 PM-6:45 PM

Minimal Residual Disease after HCT 9:00 AM-10:00 AM

Duncan Purtill

Darren R. Feldman

Alberto Mussetti

Susan Prockop

Sheila Kenny

Holly Wallace, Pam Grant-Navarro, Jen Feustel and Kathy Choo

Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment 4:45 PM-6:45 PM

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective Analysis in the Rituximab Era 4:45 PM-6:45 PM

101 Phase I/II Study of Paclitaxel Plus Ifosfamide Followed By HighDose Paclitaxel, Ifosfamide, and Carboplatin with Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors 4:45 PM-6:45 PM

Third Party Donor Derived EBV Specific T Cells for the Treatment of Refractory EBV-Related Post-Transplant Lymphomas 4:45 PM-6:45 PM

POSTER PRESENTATIONS - 6:45 PM-7:45 PM Roni Tamari

Ex-Vivo T-Cell Depleted Allogeneic (TCD) Hematopoietic Stem Cell Transplantation for Advanced Chronic Myelofibrosis: MSKCC Experience

Doris Ponce

Intensified Mycophenolate Mofetil (MMF) Dosing Is Safe from the Standpoint of Engraftment and Reduces Severe Acute GraftVersus-Host Disease (aGVHD) after Double-Unit Cord Blood Transplantation (DCBT): An Analysis of 173 Patients

Doris Ponce

High Day 28 ST2 Biomarker Levels Predict Severe Day 100 Acute Graft-Versus-Host Disease and Day 180 Transplant-Related Mortality after Double-Unit Cord Blood Transplantation

Cathy Featherstone and Heather Hylton

Safety and Efficiency of Administration of Foscarnet in an Intensive Adult Bone Marrow Transplant Clinic: A Multidisciplinary Approach

Holly Wallace, Pam Grant-Navarro, Jen Feustel and Kathy Choo

Amyloid Treatment Pearls: Standardizing an Approach to Patient Care

Beep Beep Beep: Rescuing Patients and Nurses from Pump Alarms on an Inpatient BMT Unit

Roni Tamari

Miguel-Angel Perales

Infusing Technology into the BMT Nursing Process

Gabriela Hobbs

A Novel Reduced Intensity Conditioning Regimen for Patients with High Risk Hematologic Malignancies Undergoing Conventional Allogeneic Stem Cell Transplantation

Sunday, March 2, 2014 PODIUM PRESENTATIONS Gabriela Hobbs

Do Patients with High Risk or Relapsed Core Binding Factor Acute Myeloid Leukemia Benefit from Salvage Allogeneic Stem Cell Transplantation? 10:30 AM-12:00 PM

Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome 10:30 AM-12:00 PM

Next Generation Sequencing to Characterize Post-transplant T cell Recovery 12:30 PM-2:00 PM

MSKCC 2014 BMT  
MSKCC 2014 BMT  

2014 BMT Tandem Meeting Speakers